Ariad names Paris Panayiotopoulos CEO

21 December 2015

Ariad Pharmaceuticals (Nasdaq: ARIA) has named Paris Panayiotopoulos president and chief executive officer, effective January 1, 2016.

Mr Panayiotopoulos will succeed Harvey Berger, the founder, chairman and chief executive of Ariad. Mr Panayiotopoulos joins Ariad from his current position of president of EMD Serono. Prior to this, he was at US drug major Eli Lilly & Co (NYSE: LLY).

Alexander Denner, chairman of the CEO search committee, said: “We are excited to welcome Paris as our new chief executive. The search committee conducted an extremely thorough process, and we are very pleased with this outcome. Paris’ track record of global and turnaround success, both strategically and operationally, is just what the company needs at this time.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK